Genmab
Genmab on podcasts: where it advertises, what it's offering listeners, and what hosts say about it when they're not being paid.
Sponsorships
No ad reads on tracked podcasts in the last 30 days. Hosts are talking about it anyway — see the earned side.
What hosts are saying
Most mentioned on
In their words
“Danish firm Genmab's shares are up sharply, up over about 8% in morning trading. Combination medicine with Abbvie, the US firm for lymphoma. They've had positive results from a trial there. It's cutting the risk of disease progression or death by more than 50%.”
Shares up 8% on positive lymphoma trial results showing over 50% risk reduction for disease progression or death.
▶ Hear it“Let's start with the biotech firm Gen Mab. Yes. So, they're gaining as much as 8.7% today. Um, and that's after they posted the latest data for their lymphoma drug. That's really impressed analysts... their drug has cut the risk of disease progression or death. It's been found to do that to cut that by 51%.”
Company's lymphoma drug showed impressive phase 3 data cutting disease progression/death risk by 51%, and ovarian cancer drug showed positive phase 2 data, driving stock up 8.7%.
▶ Hear itThe full picture
A weekly email with where each one advertised and what hosts said about them. Free.